The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer
Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC). Nowadays, immune response checkpoint inhibitors (monoclonal antibodies) are actively introd...
Saved in:
| Main Authors: | E. I. Smolenov, G. V. Afonin, V. S. Usachev, D. D. Kudryavtsev, I. V. Kolobaev, S. A. Ivanov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2021-06-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/727 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01) -
Concurrent versus sequential immunotherapy with chemoradiotherapy for unresectable stage III non-small-cell lung cancer: a retrospective study
by: Zhou Meng-Xi, et al.
Published: (2025-01-01) -
Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study
by: Xiongtao Yang, et al.
Published: (2025-12-01) -
Modern approaches to esophageal squamous cell carcinoma therapy: paradigm shift?
by: E. I. Smolenov, et al.
Published: (2023-12-01) -
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC
by: Jay M. Lee, MD, et al.
Published: (2025-08-01)